Junge A, et al. - Since CD16 has been shown to exert key functions to bring antibody-dependent cell-mediated cytotoxicity response, researchers investigated the prognostic impact of aberrant CD16 expression in AML patients at diagnosis. For this purpose, they analyzed AML patients undergoing intensive chemotherapy for aberrant CD16+ and CD56+ natural killer-cell marker expression. They found adverse survival outcomes in AML patients with aberrant CD16 and CD56 expression. For CD16+/CD56+ patients vs CD16-/CD56-, an event-free survival of 5.7 months vs 7.1 months and an overall survival of 10.6 months vs 52.2 months, respectively, was also reported.